Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol

Inclusion Criteria:

* The subject is of age 18\~65, both male and female;
* Newly pathologically diagnosed with classical Hodgkin's lymphoma (lymphocyte depletion type, lymphocyte rich type, nodular sclerosing type, and mixed cellularity type), who had not accepted previous treatment;
* Had stage IIB, III or IV disease, as assessed by the Ann Arbor classification;
* ECOG≤2, life expectancy ≥3 month;
* A negative serum pregnancy test required for sexually active women of childbearing potential;
* The subject voluntarily gives written informed consent to participate in the study.

Exclusion Criteria:

* Hematopoietic function:

  * Leukocyte \<3,500/mm3（3.5×109/L）
  * Neutrophils \<1,500/mm3（1.5×109/L）
  * Platelets \<100,000/mm3（100×109/L）
* Intolerance to any of the active ingredients and/or excipients in the study medications;
* Severe central nervous system disorders and mental illness;
* Severe heart disease (congestive heart failure, uncontrolled hypertension, unstable coronary artery disease, or myocardial infarction, or severe arrhythmia). Echocardiography showed resting left ventricular ejection fraction (LVEF) \< 50%);
* History of severe lung disease;
* AST or ALT\>2.5×ULN，total bilirubin≥1.5×ULN，serum creatinine\>1.5×ULN (for subject with liver metastases: AST or ALT\>5xULN, total bilirubin ≥ 3xULN);
* Uncontrolled, systemic, active infection；
* Positive serology to HIV;
* HBsAg positive subjects can still be enrolled in the study, but researchers should follow "The consensus on the Treatment of Lymphoma with Hepatitis B Infections" to observe closely and/or provide prophylactic anti-HBV therapy (as per investigator's decision);
* Other previous or concomitant malignancy, except for basal cell carcinoma and/or cervical carcinoma in situ;
* The subject is receiving an investigational drug, or has participated in an investigational study within 30 days prior to screening;
* The subject is pregnant or lactating; or subjects of childbearing potential (both women and man subjects) do not want to take effective contraceptive measures during study period or within 3 months after study completes;
* Investigators believe subjects not suitable to participate in the study for other reasons.